242 related articles for article (PubMed ID: 35257201)
1. The role of imaging in diagnosis and management of malignant peritoneal mesothelioma: a systematic review.
Carlson B; Harmath C; Turaga K; Kindler HL; Armato SG; Straus C
Abdom Radiol (NY); 2022 May; 47(5):1725-1740. PubMed ID: 35257201
[TBL] [Abstract][Full Text] [Related]
2. Malignant Peritoneal Mesothelioma Features Shown by FDG-PET/CT.
Kuribayashi K; Kitajima K; Minami T; Ikeda M; Yamakado K; Kijima T
Cancer Diagn Progn; 2022; 2(6):654-660. PubMed ID: 36340443
[TBL] [Abstract][Full Text] [Related]
3. First-line chemotherapy with pemetrexed plus cisplatin for malignant peritoneal mesothelioma.
Fujimoto E; Kijima T; Kuribayashi K; Negi Y; Kanemura S; Mikami K; Doi H; Kitajima K; Nakano T
Expert Rev Anticancer Ther; 2017 Sep; 17(9):865-872. PubMed ID: 28594258
[TBL] [Abstract][Full Text] [Related]
4. CT differentiation of diffuse malignant peritoneal mesothelioma and peritoneal carcinomatosis.
Liang YF; Zheng GQ; Chen YF; Song H; Yin WJ; Zhang L
J Gastroenterol Hepatol; 2016 Apr; 31(4):709-15. PubMed ID: 26645426
[TBL] [Abstract][Full Text] [Related]
5. 18F-FDG PET/CT in a recurrent diffuse malignant peritoneal mesothelioma.
Cao Q; Lu M; Heath J; Hausner PF; Alexander HR; Dilsizian V; Chen W
Clin Nucl Med; 2012 May; 37(5):492-4. PubMed ID: 22475902
[TBL] [Abstract][Full Text] [Related]
6. Prognostic role of radiological peritoneal cancer index in malignant peritoneal mesothelioma: national cohort study.
Salo SAS; Lantto E; Robinson E; Myllärniemi M; Laaksonen S; Salo JA; Rantanen T; Ilonen I
Sci Rep; 2020 Aug; 10(1):13257. PubMed ID: 32764701
[TBL] [Abstract][Full Text] [Related]
7. [Imaging of peritoneal mesotheliomas].
Lewin M; Arrivé L; Wendum D; Monnier-Cholley L; Bouttier E; Tubiana JM
J Radiol; 1996 Sep; 77(9):649-56. PubMed ID: 8944121
[TBL] [Abstract][Full Text] [Related]
8. Peritoneal mesothelioma: the site of origin matters.
Kindler HL
Am Soc Clin Oncol Educ Book; 2013; ():182-8. PubMed ID: 23714495
[TBL] [Abstract][Full Text] [Related]
9. CT differentiation of malignant peritoneal mesothelioma and tuberculous peritonitis.
Yin WJ; Zheng GQ; Chen YF; Chen DQ; Sun NN; Yang YX; Sun XY; Kang LQ
Radiol Med; 2016 Apr; 121(4):253-60. PubMed ID: 26661955
[TBL] [Abstract][Full Text] [Related]
10. CT of peritoneal mesothelioma: analysis of eight cases.
Whitley NO; Brenner DE; Antman KH; Grant D; Aisner J
AJR Am J Roentgenol; 1982 Mar; 138(3):531-5. PubMed ID: 6978005
[TBL] [Abstract][Full Text] [Related]
11. Localized biphasic malignant mesothelioma presenting as a giant pelvic wall mass: a rare case report and literature review.
Liu Y; Wu J; Zhao Y; Zhang P; Hua Z; Dong W; Lin T; Liu A
BMC Med Imaging; 2020 May; 20(1):48. PubMed ID: 32375654
[TBL] [Abstract][Full Text] [Related]
12. A case of malignant peritoneal mesothelioma with a Fitz-Hugh-Curtis syndrome-like imaging finding.
Iwadare T; Kimura T; Nagata Y; Suzuki H; Kunimoto H; Kitabatake H; Seki A; Ochi Y; Hara E; Umemura T
Clin J Gastroenterol; 2023 Jun; 16(3):372-376. PubMed ID: 36781827
[TBL] [Abstract][Full Text] [Related]
13. [Pathological classification of malignant peritoneal mesothelioma and comparative analysis with peritoneal carcinomatosis].
Zhang GZ; Zheng GQ; Wei F; Liu YY; Song H; Liang YF
Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2023 Jul; 41(7):541-546. PubMed ID: 37524680
[No Abstract] [Full Text] [Related]
14. Effectiveness of intraperitoneal hyperthermo-chemotherapy for malignant peritoneal mesothelioma and estimation of its effect by repeated FDG-PET: a case report.
Yamaguchi S; Asao T; Tsutsumi S; Fujii T; Yamauchi H; Kigure W; Morita H; Yajima R; Suto T; Kuwano H
Hepatogastroenterology; 2011; 58(107-108):861-4. PubMed ID: 21830405
[TBL] [Abstract][Full Text] [Related]
15. 18F-fluoro-2-deoxy-d-glucose positron emission tomography/computed tomography fused imaging in malignant mesothelioma patients: looking from outside is not enough.
Roca E; Laroumagne S; Vandemoortele T; Berdah S; Dutau H; Maldonado F; Astoul P
Lung Cancer; 2013 Feb; 79(2):187-90. PubMed ID: 23206832
[TBL] [Abstract][Full Text] [Related]
16. Clinical value of fluorodeoxyglucose-positron emission tomography/computed tomography in differentiation of malignant mesothelioma from asbestos-related benign pleural disease: an observational pilot study.
Yildirim H; Metintas M; Entok E; Ak G; Ak I; Dundar E; Erginel S
J Thorac Oncol; 2009 Dec; 4(12):1480-4. PubMed ID: 19875971
[TBL] [Abstract][Full Text] [Related]
17. Epidemiology of malignant peritoneal mesothelioma: A population-based study.
Salo SAS; Ilonen I; Laaksonen S; Myllärniemi M; Salo JA; Rantanen T
Cancer Epidemiol; 2017 Dec; 51():81-86. PubMed ID: 29080447
[TBL] [Abstract][Full Text] [Related]
18. Concerning CT features predict outcome of treatment in patients with malignant peritoneal mesothelioma.
Sugarbaker PH; Chang D; Jelinek JS
Eur J Surg Oncol; 2021 Sep; 47(9):2212-2219. PubMed ID: 33888394
[TBL] [Abstract][Full Text] [Related]
19. Nivolumab for malignant peritoneal mesothelioma.
Tanaka T; Miyamoto Y; Sakai A; Fujimoto N
BMJ Case Rep; 2020 Nov; 13(11):. PubMed ID: 33257382
[TBL] [Abstract][Full Text] [Related]
20. Clinical utility of 18F-FDG positron emission tomography in malignant peritoneal mesothelioma.
Domènech-Vilardell A; Rasiej MJ; Taub RN; Ichise M
Q J Nucl Med Mol Imaging; 2016 Mar; 60(1):54-61. PubMed ID: 24727854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
